Get to know our clinical trials
Trial of dupilumab in patients with uncontrolled chronic rhinosinusitis without nasal polyposis (CRS without nasal polyposis).
EL OBJETO DEL ESTUDIO ES EVALUAR LA SEGURIDAD Y LA EFICACIA DE DUPILUMAB EN LA REDUCCIÓN DE LOS SIGNOS Y SÍNTOMAS EN PACIENTES CON RINOSINUSITIS CRÓNICA SIN POLIPOSIS NASAL
- ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE 2 PARTES PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE DUPILUMAB EN PACIENTES CON RINOSINUSITIS CRÓNICA SIN POLIPOSIS NASAL (RSC SIN PN) NO CONTROLADA. INMUNOTERAPIA
- Code EudraCT: 2020-003117-35
- Protocol number: EFC16723
- Promoter: Sanofi-Aventis S.A.
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.